PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Clopidogrel - Prevention of atherothrombotic events - Acute Coronary Syndrome
PAD Profile : Clopidogrel - Prevention of atherothrombotic events - Acute Coronary Syndrome
Keywords :
ACS, dual antiplatelet therapy, DAPT, triple antiplatelet therapy
Brand Names Include :
Plavix
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 July 2023
Committee Recommendations
Date
Committee Name
Narrative
29 July 2020
Surrey Heartlands Medicines Safety Committee (MSC)
Co-prescribing of antiplatelets / anticoagulants may be requested by a specialist in a number of scenarios.
The Medicines safety Group have produced an aide memoire to list the information that must be available to the primary care clinican to support the safe prescribing of dual / triple therapies in primary care.
See below for document: "Dual antiplatelet-anticoagulant therapy - Aide memoire for managing hospital requests"
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC clopidogrel has been considered by the PCN and has been assigned a GREEN traffic light status.
NOTE - the branded product, Plavix, was considered BLACK at the PCN in May 2017.
30 January 2013
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Surrey Heart and Stroke Network held a consensus meeting on 18th January 2013 to consider a pathway for the use of antiplatelets in ACS. The network considered the available NICE guidance in relation to acute coronary syndromes for clopidogrel, prasugrel and ticagrelor. The meetings aim was to agree an implementation strategy within NHS Surrey with an appropriate treatment pathway noting that all 3 agents are currently a treatment option. The recommendations made were as follows: Remain with the current Surrey recommendation that clopidogrel should be the preferred antiplatelet for the treatment of acute coronary syndromes (in combination with aspirin). Ticagrelor (or prasugrel) remain a treatment option but would normally be reserved for patients who are clopidogrel resistant. Patients will continue to be loaded with clopidogrel during ambulance transfer. The PCN concurred with the recommendations of the Surery heart network noting a request to review the recommendation in 9 months time.
04 December 2009
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Despite all of the generic clopidogrel preparations having a license for use in ACS, there are some restrictions applied to their Marketing Authorisations. However, the committee were satisfied that this restriction was merely a Patent protection issue and would support the prescribing and dispensing of generic clopidogrel for all of their licensed indications including in combination with aspirin for ACS
Associated BNF Codes
02. Cardiovascular System
02.09.00. Antiplatelet drugs